- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Wells Fargo initiates Pyxis Oncology stock with overweight rating | 4 | Investing.com | ||
| 06.07. | H.C. Wainwright bestätigt Kaufempfehlung für Pyxis Oncology Aktie | 21 | Investing.com Deutsch | ||
| 06.07. | H.C. Wainwright reiterates Pyxis Oncology stock rating at buy | 3 | Investing.com | ||
| 02.07. | Pyxis Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| PYXIS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 02.07. | Leerink cuts Pyxis Oncology stock price target on valuation | 2 | Investing.com | ||
| 30.06. | Pyxis Oncology raises $50 million in private placement | 5 | Investing.com | ||
| 30.06. | Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones | 505 | GlobeNewswire (Europe) | Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase... ► Artikel lesen | |
| 15.06. | Pyxis Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Pyxis Oncology, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 14.05. | Pyxis Oncology GAAP EPS of -$0.37 misses by $0.01 | 8 | Seeking Alpha | ||
| 14.05. | Pyxis Oncology, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 07.05. | Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer | 215 | GlobeNewswire (Europe) | BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment... ► Artikel lesen | |
| 17.04. | Pyxis Oncology legt vielversprechende präklinische Daten für MICVO bei Kopf- und Halskrebs vor | 12 | Investing.com Deutsch | ||
| 17.04. | Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 | 2 | GlobeNewswire (USA) | ||
| 24.03. | H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target | 2 | Investing.com | ||
| 24.03. | Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data | 10 | Investing.com | ||
| 24.03. | Stifel cuts Pyxis Oncology stock price target on financing assumptions | 15 | Investing.com | ||
| 23.03. | Pyxis Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 23.03. | Jefferies hebt Kursziel für Pyxis Oncology nach Studiendaten an | 4 | Investing.com Deutsch | ||
| 23.03. | Jefferies raises Pyxis Oncology stock price target on drug data | 1 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,70 | +3,33 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| EVOTEC | 3,464 | +0,93 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| BB BIOTECH | 55,70 | +1,27 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| VALNEVA | 2,291 | +0,04 % | Valneva streicht Jobs - warum die Aktie dennoch steigt | ||
| AMGEN | 355,85 | +0,13 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,40 | -0,82 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | -1,35 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| BAVARIAN NORDIC | 23,480 | -0,51 % | Bavarian Nordic A/S: Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years | MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virusApproval further strengthens MVA-BN's position in... ► Artikel lesen | |
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M |
Das Unternehmen PYXIS ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PYXIS ONCOLOGY INC finden Sie auf Wallstreet Online.